CMPO vs. TNGX, PRCH, UPST, PWP, CIFR, SII, IREN, ML, BITF, and CORZ
Should you be buying CompoSecure stock or one of its competitors? The main competitors of CompoSecure include Tango Therapeutics (TNGX), Porch Group (PRCH), Upstart (UPST), Perella Weinberg Partners (PWP), Cipher Mining (CIFR), Sprott (SII), Iris Energy (IREN), MoneyLion (ML), Bitfarms (BITF), and Core Scientific (CORZ).
CompoSecure (NASDAQ:CMPO) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap business services companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment, community ranking and earnings.
CompoSecure has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than CompoSecure, indicating that it is currently the more affordable of the two stocks.
CompoSecure has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
CompoSecure has a net margin of 5.14% compared to Tango Therapeutics' net margin of -299.88%. CompoSecure's return on equity of -11.00% beat Tango Therapeutics' return on equity.
CompoSecure currently has a consensus target price of $12.33, suggesting a potential upside of 94.38%. Tango Therapeutics has a consensus target price of $14.17, suggesting a potential upside of 104.72%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than CompoSecure.
CompoSecure received 2 more outperform votes than Tango Therapeutics when rated by MarketBeat users. Likewise, 76.00% of users gave CompoSecure an outperform vote while only 62.96% of users gave Tango Therapeutics an outperform vote.
In the previous week, Tango Therapeutics had 16 more articles in the media than CompoSecure. MarketBeat recorded 17 mentions for Tango Therapeutics and 1 mentions for CompoSecure. CompoSecure's average media sentiment score of 1.75 beat Tango Therapeutics' score of 0.28 indicating that CompoSecure is being referred to more favorably in the media.
37.6% of CompoSecure shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 75.0% of CompoSecure shares are owned by company insiders. Comparatively, 6.2% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
CompoSecure beats Tango Therapeutics on 11 of the 18 factors compared between the two stocks.
Get CompoSecure News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CompoSecure Competitors List
Related Companies and Tools
